Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

obexelimab

A humanized immunoglobulin G1 (IgG1) noncytolytic monoclonal antibody directed against the B-cell-specific cell surface antigen CD-19, Fc-engineered for increased affinity to Fc gamma receptor IIB (FcgRIIB; CD32B), with potential immunomodulatory activity. Upon administration, obexelimab simultaneously targets and binds to both CD19 and FcgRIIB expressed on the surface of B cells, and inhibits B-cell receptor (BCR) signaling and the activity of B cells without depleting the B-cells. This may alleviate manifestations of autoimmune diseases including systemic lupus erythematosus (SLE). CD19 and FcgRIIB, both expressed on the surface of B-cells, play important roles in BCR signaling, and B-cell activity and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:XMAB 5871
XMAB-5871
XMAB5871
ZB 012
ZB-012
ZB012
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search